Article Details

Immunovant Stock: Speculative Biotech With Proven Drugs (NASDAQ:IMVT) | Seeking Alpha

Retrieved on: 2022-02-05 14:52:55

Tags for this article:

Click the tags to see associated articles and topics

Immunovant Stock: Speculative Biotech With Proven Drugs (NASDAQ:IMVT) | Seeking Alpha. View article details on hiswai:

Excerpt

Immunovant is deploying its anti-FcRn monoclonal antibody IMVT-1401 ... which are also targeting the FcRn pathway with monoclonal antibodies.

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up